Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1612 1658
This examiner grants 46% of resolved cases
Walter E. Webb is an examiner in Tech Center 1600 and Art Unit 1600. The examiner has a volume of 1004 resolved cases. The allowance rate is 46.3 percent, which indicates that nearly half of the applications result in a patent grant. This volume of data provides a statistically significant basis for evaluating the examiner's historical performance and setting expectations for future prosecution outcomes.
The interview lift is 18.8 percent. This figure suggests that conducting an interview is a useful strategy for improving the probability of an allowance. The data indicates that direct communication can help resolve issues and move cases toward a grant. Additionally, the median days to allowance is 1215. This duration reflects the typical timeframe for the prosecution process to reach completion. Practitioners can use this figure to manage client expectations and plan for the time required to secure a patent.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18941686 | METHOD OF TREATING TEETH USING AN ORAL CARE ARTICLE COMPRISING A DELIVERY CARRIER AND SOLID HYDROPHILIC PARTICLES | Non-Final OA | The Procter & Gamble Company |
| 18886278 | Oral Care Compositions With Anticaries Activity | Non-Final OA | The Procter & Gamble Company |
| 18788266 | Fluoride-Free Anticavity Oral Care Compositions | Non-Final OA | The Procter & Gamble Company |
| 18713364 | METHOD OF PREPARING BIODEGRADABLE MICROCAPSULES BASED ON GELATINE | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18640956 | CONDUCTIVE ELASTOMER FOR BLADDER REGENERATION | Non-Final OA | Northwestern University |
| 18884334 | SOLUBLE FIBER LOZENGE | Non-Final OA | Altria Client Services LLC |
| 18734661 | COSMETIC COMPOSITION INCLUDING AN ALOE-TREATED COLORANT | Final Rejection | L'OREAL |
| 18258011 | DYEING COMPOSITION BASED ON 2-GAMMA-HYDROXYPROPYL-PARA-PHENYLENEDIAMINE AND ON A PHOSPHORIC SURFACTANT | Final Rejection | L'Oreal |
| 18266900 | PROCESS FOR LIGHTENING KERATIN FIBRES | Non-Final OA | L'OREAL |
| 19044040 | Peroxymonosulfate Whitening Strips | Non-Final OA | Colgate-Palmolive Company |
| 19011108 | Oral Care Compositions and Methods of Use | Non-Final OA | Colgate-Palmolive Company |
| 18808749 | Metal Salt Compositions | Non-Final OA | Colgate-Palmolive Company |
| 18354302 | COMPOSITIONS AND RELATED METHODS | Non-Final OA | Colgate-Palmolive Company |
| 18256515 | Oral Care Compositions with a Natural Sweetener System | Final Rejection | Colgate-Palmolive Company |
| 18109223 | Oral Care Compositions | Final Rejection | Colgate-Palmolive Company |
| 18006482 | Inhibitors of the Artemin Pathway for Treatment of Cancer | Final Rejection | The University of Chicago |
| 18643489 | Oral Health Composition Comprising Purified Biosurfactants and/or Their Derivatives | Final Rejection | Locus Solutions IPCo, LLC |
| 18294373 | DEODORANT COMPOSITIONS | Final Rejection | Conopco, Inc., d/b/a UNILEVER |
| 18032094 | CELLULAR MEMBRANE VESICLES AND USES THEREOF | Non-Final OA | University of Delaware |
| 18413349 | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | Final Rejection | ASTRAZENECA AB |
| 18293248 | COSMETIC COMPOSITION | Non-Final OA | KAO CORPORATION |
| 18019634 | 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE FOR TREATING THROMBOCYTHEMIA | Non-Final OA | Constellation Pharmaceuticals, Inc. |
| 18367118 | METHOD FOR IMPROVING THE PHARMACEUTIC PROPERTIES OF MICROPARTICLES COMPRISING DIKETOPIPERAZINE AND AN ACTIVE AGENT | Non-Final OA | MannKind Corporation |
| 18928260 | WOUND CLEANSING METHOD | Non-Final OA | OSARTIS GmbH |
| 18005425 | COOLING SENSATION COMPOSITIONS | Final Rejection | GIVAUDAN SA |
| 18271583 | EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF | Final Rejection | The United States of America,as represented by the Secretary,Department of Health and Human Services |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy